Active, not recruitingPHASE1, PHASE2NCT05541627

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Studying Huntington disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)
Intervention
AB-1001 Gene Therapy(genetic)
Enrollment
5 enrolled
Eligibility
18-65 years · All sexes
Timeline
2022 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05541627 on ClinicalTrials.gov

Other trials for Huntington disease

Additional recruiting or active studies for the same condition.

See all trials for Huntington disease →

← Back to all trials